Search research articles
Contact Us
Filters
Showing results (41-50 of 52) with videos related to
Page
of 6
Sort By:
AIDS (London, England)
|
March 14, 2020
Plasma nucleotide reverse transcriptase inhibitor concentration and their associations with liver and renal parameters in people living with HIV
Xinzhu Wang, Marta Boffito, Laura Dickinson, et al.
Therapeutic Drug Monitoring
|
June 4, 2008
Lopinavir/ritonavir pharmacokinetics in HIV/HCV-coinfected patients with or without cirrhosis
Valeria Micheli, Mario Regazzi, Laura Dickinson, et al.
The Journal of Antimicrobial Chemotherapy
|
November 23, 2019
Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: a sub-study of the NEAT001/ANRS143 randomized trial
Laura Dickinson, Rohan Gurjar, Wolfgang Stöhr, et al.
Clinical Pharmacokinetics
|
December 31, 2015
Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study
Laura Dickinson, Janaki Amin, Laura Else, et al.
The Pharmacogenomics Journal
|
October 20, 2022
Influence of UGT1A1 and SLC22A6 polymorphisms on the population pharmacokinetics and pharmacodynamics of raltegravir in HIV-infected adults: a NEAT001/ANRS143 sub-study
Rohan Gurjar, Laura Dickinson, Daniel Carr, et al.
Plos One
|
July 21, 2021
Associations between plasma nucleoside reverse transcriptase inhibitors concentrations and cognitive function in people with HIV
Davide De Francesco, Xinzhu Wang, Laura Dickinson, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
March 10, 2022
Pharmacokinetics of ß-d-N4-Hydroxycytidine, the Parent Nucleoside of Prodrug Molnupiravir, in Nonplasma Compartments of Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection
Richard FitzGerald, Laura Dickinson, Laura Else, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
December 21, 2020
Infant Exposure to Dolutegravir Through Placental and Breast Milk Transfer: A Population Pharmacokinetic Analysis of DolPHIN-1
Laura Dickinson, Stephen Walimbwa, Yashna Singh, et al.
Ebiomedicine
|
February 28, 2025
Development of an oral regimen of unithiol for the treatment of snakebite envenoming: a phase 1 open-label dose-escalation safety trial and pharmacokinetic analysis in healthy Kenyan adults
Michael Abouyannis, Yvonne K Nyambura, Samson Ngome, et al.
The Journal of Antimicrobial Chemotherapy
|
June 16, 2026
A randomized controlled Phase I de-escalation trial of molnupiravir and nirmatrelvir/ritonavir combination for mild-moderate SARS-CoV-2 infection
Saye H Khoo, Richard FitzGerald, Christopher J Edwards, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 52) with videos related to
Sort By:
Page
of 6
AIDS (London, England)
|
March 14, 2020
Plasma nucleotide reverse transcriptase inhibitor concentration and their associations with liver and renal parameters in people living with HIV
Xinzhu Wang, Marta Boffito, Laura Dickinson, et al.
Therapeutic Drug Monitoring
|
June 4, 2008
Lopinavir/ritonavir pharmacokinetics in HIV/HCV-coinfected patients with or without cirrhosis
Valeria Micheli, Mario Regazzi, Laura Dickinson, et al.
The Journal of Antimicrobial Chemotherapy
|
November 23, 2019
Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: a sub-study of the NEAT001/ANRS143 randomized trial
Laura Dickinson, Rohan Gurjar, Wolfgang Stöhr, et al.
Clinical Pharmacokinetics
|
December 31, 2015
Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study
Laura Dickinson, Janaki Amin, Laura Else, et al.
The Pharmacogenomics Journal
|
October 20, 2022
Influence of UGT1A1 and SLC22A6 polymorphisms on the population pharmacokinetics and pharmacodynamics of raltegravir in HIV-infected adults: a NEAT001/ANRS143 sub-study
Rohan Gurjar, Laura Dickinson, Daniel Carr, et al.
Plos One
|
July 21, 2021
Associations between plasma nucleoside reverse transcriptase inhibitors concentrations and cognitive function in people with HIV
Davide De Francesco, Xinzhu Wang, Laura Dickinson, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
March 10, 2022
Pharmacokinetics of ß-d-N4-Hydroxycytidine, the Parent Nucleoside of Prodrug Molnupiravir, in Nonplasma Compartments of Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection
Richard FitzGerald, Laura Dickinson, Laura Else, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
December 21, 2020
Infant Exposure to Dolutegravir Through Placental and Breast Milk Transfer: A Population Pharmacokinetic Analysis of DolPHIN-1
Laura Dickinson, Stephen Walimbwa, Yashna Singh, et al.
Ebiomedicine
|
February 28, 2025
Development of an oral regimen of unithiol for the treatment of snakebite envenoming: a phase 1 open-label dose-escalation safety trial and pharmacokinetic analysis in healthy Kenyan adults
Michael Abouyannis, Yvonne K Nyambura, Samson Ngome, et al.
The Journal of Antimicrobial Chemotherapy
|
June 16, 2026
A randomized controlled Phase I de-escalation trial of molnupiravir and nirmatrelvir/ritonavir combination for mild-moderate SARS-CoV-2 infection
Saye H Khoo, Richard FitzGerald, Christopher J Edwards, et al.
Page
of 6